Newron Pharmaceuticals (SIX: NWRN)

Last close As at 12/07/2024

CHF8.07

−0.03 (−0.37%)

Market capitalisation

CHF154m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber

    CEO

Balance Sheet

Forecast net cash (€m)

29.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (18.0) 9.8 36.3
Relative (19.2) 2.7 21.9
52 week high/low CHF11.0/CHF4.2

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). In April/May 2024, Newron shared positive results from a Phase II/III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS (primary and key secondary endpoints met). In January 2024, positive final results (12-month data for the full patient cohort) were announced for a Phase II trial (study 014/015) in TRS patients. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. With these encouraging results in hand, Newron now intends to begin a potentially pivotal, multinational Phase III schizophrenia programme (expected to start in 2024). In its FY23 results, Newron recorded total revenue of €9.1m (up 48.6% y-o-y) for the period, primarily derived from Xadago-related royalty income.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023A 9.1 (11.2) (16.0) (89.81) N/A N/A
2024E 24.3 2.1 (2.6) (14.12) N/A N/A
2025E 27.1 3.3 (0.8) (4.31) N/A N/A

Update

Healthcare

Newron Pharmaceuticals — Dyskinesia deal delivered

edison tv

Healthcare

Newron Pharmaceuticals – EKF interview

Flash note

Healthcare

Newron Pharmaceuticals — Sarizotan fails to shine

Update

Healthcare

Newron Pharmaceuticals — Seeing STARS

Update

Healthcare

Newron Pharmaceuticals — Evenamide down but not out

Update

Healthcare

Newron Pharmaceuticals — Next up – R&D day

Flash note

Healthcare

Newron Pharmaceuticals — Xadago receives FDA approval in PD

Update

Healthcare

Newron Pharmaceuticals — Marching into 2017

Outlook

Healthcare

Newron Pharmaceuticals — Update 2 September 2016

Flash note

Healthcare

Newron Pharmaceuticals — Update 31 March 2016

Flash note

Healthcare

Newron Pharmaceuticals — Update 17 March 2016

Update

Healthcare

Newron Pharmaceuticals — Update 14 March 2016

Update

Healthcare

Newron Pharmaceuticals — Update 20 December 2015